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thyroid cancer expert including Nuclear Medicine Phy-
sicians and Endocrinologists to provide a consensus on 
the post-surgical ablation in thyroid cancer patients. The 
task force had no conflict of interest and had no commer-
cial support. A number of specific topics were selected 
and the members selected relevant papers by searching in 
the Pubmed for articles published from 2000 to January 
2015. Selected studies were categorized by level of evi-
dence, and the recommendations were graded according 
to the level of evidence as high (A), moderate (B), or low 
(C).
Keywords Radioiodine · Thyroid ablation · Thyroid 
cancer · Thyroglobulin · rhTSH
Introduction
Post-surgical ablation of thyroid remnant with radioactive 
iodine (RAI) (remnant ablation) in differentiated thyroid 
cancer (DTC) is aimed to facilitate the early detection of 
recurrence based on serum thyroglobulin (Tg) measure-
ment and/or RAI whole-body scan (WBS) and to obtain 
a post-therapy WBS, whose results may change the initial 
staging by identifying previously undiagnosed disease. In 
addition, RAI ablation may represent an adjuvant therapy 
by cleaning persistent microscopic foci of cancer which 
can be present in the thyroid remnant especially in papil-
lary thyroid cancer (PTC) that are frequently multifocal. 
While the first aim, remnant ablation, is related to follow-
up in any patient regardless of his specific risk, the second 
one, adjuvant therapy, is advocated as a tool to reduce the 
rates of disease recurrence or cause-specific mortality [1], 
and thus its use must be justified according to a real risk 
of recurrence. Indeed, in patients at the lowest risk for 
Abstract Post-surgical ablation of thyroid  remnant with 
radioactive iodine (RAI) in differentiated thyroid cancer 
(DTC) is aimed to destroy any thyroid remnant in the thy-
roid bed (remnant ablation) and any microscopic foci of 
cancer cells eventually present within the thyroid remnant 
(adjuvant therapy). The present text is an attempt to offer 
practice guidelines for the indication of thyroid ablation 
and the preparation of DTC patients considering the latest 
achievement in the field and the changing epidemiology of 
DTC observed in the last 10 years.
Methodology The executive committee of the Ital-
ian Society of Endocrinology appointed a task force of 
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recurrence and mortality several studies have shown no 
benefit of remnant ablation [2]. Benefit becomes evident 
in patients considered at intermediate [3] or high risk, par-
ticularly in terms of reduced recurrence rate and possibly of 
reduced mortality.
Based on this consideration, several authoritative guide-
lines have restricted the indication for RAI ablation to spe-
cific categories of patients considered at significant risk of 
recurrence or death. Since selection of patients for thyroid 
ablation is not the aim of this guideline, we refer to them 
for further reading.
Here we will limit our discussion to the choice of the 
most appropriate activity of 131I (low or high) to be used 
whenever thyroid ablation has been decided, including the 
definition of successful thyroid ablation and the method of 
preparation for RAI administration.
Definition of successful remnant ablation
In the past, successful remnant ablation was defined as the 
absence of visible RAI uptake on a diagnostic RAI WBS 
performed 6–12 months after remnant ablation. With the 
introduction of serum Tg measurement and neck ultra-
sound in clinical practice, the use of performing diagnostic 
WBS has been largely abandoned. Indeed, both serum Tg 
determination [4–8] and neck sonography examination [9] 
are much more sensitive compared to diagnostic WBS in 
detecting the existence of persistent or recurrent disease 
[4–8]. Nowadays, the most accepted definition of success-
ful thyroid ablation is an undetectable stimulated serum 
Tg (or an undetectable basal serum Tg if using ultra-
sensitive Tg assays) combined with undetectable serum 
anti-thyroglobulin antibodies (TgAb) and a negative neck 
ultrasound.
TgAb are commonly identified in patients with differ-
entiated follicular cell-derived thyroid cancer. Their fre-
quency in patients with DTC is approximately 20–25 % 
[10]. In case of positive TgAb, serum Tg cannot be use as 
a predictor of ablation and we have to rely on neck ultra-
sound and on the trend of serum TgAb. A diagnostic WBS 
may be considered in this setting. Antibody levels may 
serve as a surrogate biochemical marker of disease per-
sistence and response to therapy. However, the timing of 
testing and the duration to see a maximal response appear 
to differ from Tg levels in patients without TgAb. There 
may be an initial transient rise in TgAb titer after radioac-
tive iodine (RAI) treatment [11]. Also, it has been shown 
that the eventual disappearance of TgAb takes approxi-
mately 2–3 years on average. Complete ablation of thy-
roid tissue with its antigenic components results in the 
disappearance of antibodies to all major thyroid antigens 
[10–12].
Preparation for RAI ablation
Remnant ablation has been traditionally performed after 
thyroid hormone withdrawal to increase endogenous thy-
roid-stimulating hormone (TSH) to levels sufficient to 
induce robust RAI uptake in thyroid cells. Empirically, it 
is estimated that a TSH of >30 mU/L is a good cut off [13], 
but no comparative study has ever been done to document 
this assumption.
For thyroid hormone withdrawal, two possible 
approaches are used: switch from levothyroxine (LT4) to 
triiodothyronine (LT3) for some weeks [5, 6] and then stop 
LT3 for 2 weeks, or stop LT4 for 3–4 weeks without switch-
ing to LT3. These two methods have not been compared in 
terms of better outcomes of ablation.
Since several years, the alternative way of preparation 
for RAI ablation is the administration of exogenous recom-
binant human TSH (rhTSH), after a prospective, multi-
center, randomized study demonstrated that 131I remnant 
ablation with 100 mCi was equally effective after rhTSH 
stimulation or thyroid hormone withdrawal [14]. In another 
study, ablation rates were similar with either withdrawal or 
preparation with rhTSH using 50 mCi of 131I [15]. Addi-
tional evidence that preparation with thyroid hormone 
withdrawal or rhTSH has the same ablation outcome using 
both high or low radioiodine doses has been provided in 
two prospective randomized multicenter studies, one in 
France and one in the UK [16, 17]. In addition, short-term 
recurrence rates have been found to be similar in patients 
prepared with thyroid hormone withdrawal or rhTSH [18, 
19]. The preparation with rhTSH significantly improves 
quality of life [14, 20], and reduces both whole-body irradi-
ation [21, 22] and hospitalization time [23]. A recent meta-
nalysis confirms the above results [24]. Nowadays, the use 
of rhTSH is approved for remnant ablation, with any 131I 
dose, both in the United States and Europe.
Recommendation 1
Patients undergoing RAI ablation should be preferentially 
prepared by rhTSH administration. Thyroid hormone with-
drawal may be considered whenever rhTSH is not available 
or not affordable. Recommendation rating: A.
Which is the best activity of 131I to be employed 
for post‑surgical thyroid remnant ablation
Although there is a trend toward higher ablation rates with 
higher activities [25, 26], activities between 30 and 100 mCi 
of 131I generally show similar rates of successful remnant 
ablation [27–30]. A randomized study using preparation 
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with rhTSH showed that ablation rates were comparable 
with 50 mCi compared to 100 mCi [31]. A prospective, 
randomized study performed in 160 patients, comparing 
ablation with 30 and 100 mCi, after preparation with thy-
roid hormone withdrawal, found no difference in both the 
ablation rate and in the rate or recurrence during follow-up 
[32]. Recently, two prospective randomized studies in very 
large number of patients conducted in France and in the 
United Kingdom found no significant difference in the rem-
nant ablation rate using 30 or 100 mCi of 131I, either after 
preparation with thyroid hormone withdrawal or rhTSH [16, 
17]. It is worth noting, that these two studies included not 
only low-risk patients, but also patients at intermediate risk 
of recurrence, including those showing minimal extrathy-
roidal extension of the primary tumor [17] or lymph node 
metastases [16, 17]. Also in this category the authors found 
no difference between low- and high-RAI doses in terms of 
ablation success rates. This finding has been confirmed in 
a retrospective study including only patients at intermedi-
ate risk, treated with low- or high-RAI activities [33]. In this 
study, the authors were also able to demonstrate that, with 
regard to recurrences or deaths, the long-term outcome was 
not affected by the ablation dose (low or high). Concerning 
the issue of the follow-up of patients treated with low activ-
ity of 131-I and rhTSH or LT4 withdrawal, a recent study 
[19] showed that in 10 years of follow-up, the rate of recur-
rence was as low as expected (3.5 %) and similar in both 
groups. Moreover, the final outcome of these patients was 
similar at the end of follow-up (Table 1).
No definite studies are available in pediatric patients. 
For every age patients, some authors have suggested to use 
a lesion dosimetry or to give the highest dose administra-
ble based on the radiation exposure to the critical organs at 
risk, especially in high-risk group; others suggest empiric 
dosage and others an activity based on the patient’s body 
weight [34–37].
Recommendation 2
The minimum activity (30 mCi) necessary to achieve suc-
cessful remnant ablation should be utilized, particularly in 
patients at low risk and intermediate risk. Recommendation 
rating: B.
Recommendation 3
In patients considered at high risk for recurrence, or if 
residual microscopic disease is suspected or documented, 
higher activities (100 mCi or more) should be considered. 
Recommendation rating: C.
In such patients at high risk, some authors have advo-
cated the use of 124I PET as a better diagnostic proce-
dure compared to 131I whole-body scanning in staging 
disease burden. Relative to 131I planar whole-body imag-
ing, 124I PET identified as many as 50 % more foci of 
radioiodine uptake suggestive of additional residual thy-
roid tissue and/or metastases in as many as 32 % more 
patients [38]. Thus, when available, a 124I PET/CT could 
be used to perform dosimetry, to tailor treatment, instead 
of using fixed activities, and to evaluate mean absorbed 
Table 1  Guidelines for radioiodine thyroid ablation
Recommendation Rating
Preparation for RAI ablation 1. Patients undergoing RAI ablation should be preferentially prepared by  
rhTSH administration [14, 16, 17]
A
Which is the best activity of 131I to be employed  
for post-surgical thyroid remnant ablation
2. The minimum activity (30 mCi) necessary to achieve successful remnant  
ablation should be utilized, particularly in patients at low risk and  
intermediate risk [31–33]
B
3. In patients considered at high risk for recurrence, or if residual microscopic 
disease is suspected or documented, higher activities (100 mCi or more)  
should be considered [40]
C
Diagnostic RAI scanning before ablation 4. Pre-ablation diagnostic scans are seldom informative as far as the decision  
to ablate is concerned. They may be considered when a sustained suspicion of 
local or distant metastases is present to better define the activity of RAI to be 
administered or in patients with elevated levels of serum TgAb [38, 40–42]
C
Post-operative serum Tg levels and neck US 5. Post-operative serum Tg levels (in the absence of serum TgAb) and neck  
US may give additional information regarding the need for ablation and  
the radioiodine dose to be administered [47, 48]
C
Is a low-iodine diet necessary before  
remnant ablation?
6. At least in countries with mild or moderate iodine deficiency, there is no  
need to prescribe a low-iodine diet before remnant ablation. Avoidance  
of iodine-containing drugs or contrast agents is mandatory [53]
B
Post-therapy WBS after remnant ablation 7. A post-therapy WBS is recommended following remnant ablation. This is  
typically done 3–7 days after the therapeutic dose is administered [54, 55]
A
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doses both to target lesions and to non-target organs (sali-
vary glands).
Should a diagnostic RAI scanning be performed 
before ablation? Should post‑surgical serum  
Tg levels be considered in decision making?
A diagnostic RAI WBS provides information on the pres-
ence of iodine-avid thyroid tissue, which may represent the 
normal thyroid remnant or the presence of residual disease. 
There is an increasing trend to avoid diagnostic RAI scans 
because of its low impact on the decision to ablate, and 
because of concerns over 131I-induced stunning of normal 
thyroid remnants [39] and distant metastases from thyroid 
cancer [40–42]. The alternative radiopharmaceutical for 
staging, 123I, is not readily available and has a short half-
life. [43–45].
Recommendation 4
Pre-ablation diagnostic scans are seldom informative as far 
as the decision to ablate is concerned. They may be consid-
ered when a sustained suspicion of local or distant metas-
tases is present to better define the activity of RAI to be 
administered or in patients with elevated levels of serum 
TgAb. In any case, diagnostic scans should be performed 
using tracer doses of 123I (if available) or low 131I activity 
(1–2 mCi). In the last case, the therapeutic activity should 
be delivered within 72 h of the diagnostic activity to avoid 
stunning. Recommendation Rating: C.
Post‑operative serum Tg levels and neck US
Some studies investigating the clinical significance of post-
operative serum Tg levels have shown that low post-opera-
tive levels of non-stimulated Tg does not exclude persistent 
disease [46]. However, serum Tg levels may be useful for 
the indication of 131I activity to be delivered [47] and may 
represent a significant prognostic marker [48, 49].
Similar prospective information may be derived from 
the execution of neck US before ablation. US should be 
performed to check the central and lateral compartments 
of the neck whenever a cancer is fortuitously discovered at 
histology, or a preoperative US has not been done or in the 
presence of high pre-ablation serum Tg values.
Recommendation 5
Post-operative serum Tg levels (in the absence of serum 
TgAb), and neck US may give additional information 
regarding the need for ablation and the radioiodine dose to 
be administered. Recommendation Rating C.
Is a low‑iodine diet necessary before remnant ablation?
Contamination with stable iodine might theoretically 
influence the uptake of diagnostic or therapeutic doses 
of RAI [50–52]. Based on this assumption, several cent-
ers advocate preparation of the patients with a low-
iodine diet and recommend avoiding iodine contamina-
tion (intravenous contrast agents, amiodarone, or other 
iodine-containing drugs) prior to RAI therapy. However, 
no prospective study has ever determined the cut off at 
which interference may actually occur. In a retrospective 
study, aimed to compare different levels of urinary iodine 
excretion on the results of thyroid ablation in patients 
not prepared with low-iodine diet, the authors found 
no influence of different levels of urinary iodine on the 
outcome of thyroid ablation up to urinary iodine levels 
exceeding 350 µg/day of dietary iodine. In addition, the 
median level of iodine urinary content in Italy is as low 
as in mild iodine-deficient countries [53] and thus, there 
is no reason to limit the diet and the use of iodized salt in 
our country. In any case, measurement of urinary iodine 
excretion (when available) before remnant ablation may 
help in detecting the few cases with significant iodine 
contamination.
Recommendation 6
At least in countries with mild or moderate iodine defi-
ciency, there is no need to prescribe a low-iodine diet 
before remnant ablation. Avoidance of iodine-containing 
drugs or contrast agents is mandatory. If a suspicion of 
iodine contamination exists, iodine excretion should be 
evaluated starting from 20 to 30 days after the withdrawal 
of the iodine-containing drug or the contrast agent injec-
tion. Recommendation Rating: B.
Post‑therapy WBS after remnant ablation
It is recommended to perform a post-therapy WBS within 
1 week after RAI therapy. This imaging technique is of 
paramount importance in confirming the presence and the 
extent of the thyroid remnant and may disclose the pres-
ence of unsuspected metastatic foci in 10–26 % of the 
cases [55], thus allowing the reclassification of the disease 
stage [56]. Whenever possible, a SPECT-CT can be useful 
instead of a planar WBS to better define the neck uptake 
and distinguish the remnant from local lymph node or para-
tracheal tumor [57].
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Recommendation 7
A post-therapy WBS is recommended following RAI rem-
nant ablation. This is typically done 3–7 days after the ther-
apeutic dose is administered. Recommendation Rating: A.
Compliance with ethical standards 
Conflict of interest No conflict of interest.
Ethical approval This article does not contain any studies with 
human participants or animals performed by any of the authors.
Informed consent No informed consent.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Dun-
tas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez 
Franco F, Smit J, Wiersinga W (2005) Post-surgical use of radi-
oiodine (131I) in patients with papillary and follicular thyroid 
cancer and the issue of remnant ablation: a consensus report. Eur 
J Endocrinol 153:651–659
 2. Hay ID (2006) Selective use of radioactive iodine in the postop-
erative management of patients with papillary and follicular thy-
roid carcinoma. J Surg Oncol 94:692–700
 3. Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA 
(2015) Adjuvant radioactive iodine therapy is associated with 
improved survival for patients with intermediate risk papillary 
thyroid cancer. J Clin Endocrinol Metab 100(4):1529–1536
 4. Mazzaferri EL, Kloos RT (2002) Is diagnostic iodine-131 scan-
ning with recombinant human TSH (rhTSH) useful in the fol-
low-up of differentiated thyroid cancer after thyroid ablation? J 
Clin Endocrinol Metab 87:1490–1498
 5. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT 
(2002) Clinical comparison of whole-body radioiodine scan and 
serum thyroglobulin after stimulation with recombinant human 
thyrotropin. Thyroid 12:37–43
 6. Wartofsky L (2002) Management of low-risk well-differentiated 
thyroid cancer based only on thyroglobulin measurement after 
recombinant human thyrotropin. Thyroid 12:583–590
 7. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, 
Pinchera A (2002) Diagnostic 131-iodine whole-body scan may 
be avoided in thyroid cancer patients who have undetectable 
stimulated serum thyroglobulin levels after initial treatment. J 
Clin Endocrinol Metab 87:1499–1501
 8. Torlontano M, Crocetti U, D’Aloiso L, Bonfitto N, Di Gior-
gio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, 
Schlumberger M, Trischitta V (2003) Serum thyroglobulin and 
131I whole body scan after recombinant human TSH stimulation 
in the follow-up of low-risk patients with differentiated thyroid 
cancer. Eur J Endocrinol 148:19–24
 9. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Cecca-
relli C, Lippi F, Taddei D, Grasso L, Pinchera A (2003) Recom-
binant human thyrotropin-stimulated serum thyroglobulin com-
bined with neck ultrasonography has the highest sensitivity in 
monitoring differentiated thyroid carcinoma. J Clin Endocrinol 
Metab 88:3668–3673
 10. Ringel MD, Nabhan F (2013) Approach to follow-up of the 
patient with differentiated thyroid cancer and positive anti thy-
roglobulinantibodies. J Clin Endocrinol Metab 98(8):3104–3110
 11. Gorges R, Maniecki M, Jentzen W et al (2015) Development and 
clinical impact of thyroglobulin antibodies in patients with dif-
ferentiated thyroid carcinoma during the first 3 years after thy-
roidectomy. Eur J Endocrinol 153(1):49–55
 12. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, 
Masserini L, Grasso L, Pinchera A (2003) Disappearance of 
humoral thyroid autoimmunity after complete removal of thy-
roid antigens. Ann Internal Med 139:346–351
 13. Edmonds CJ, Hayes S, Kermode JC, Thompson BD (1977) 
Measurement of serum TSH and thyroid hormones in the man-
agement and treatment of thyroid carcinoma with radioiodine. Br 
J Radiol 50:799–807
 14. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, 
Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei 
R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, 
Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, 
Lassmann M, Reiners C (2006) Radioiodine ablation of thyroid 
remnants after preparation with recombinant human thyrotro-
pin in differentiated thyroid carcinoma: results of an interna-
tional, randomized, controlled study. J Clin Endocrinol Metab 
91:926–932
 15. Chianelli M, Todino V, Graziano F, Panunzi C, Pace D, Gug-
lielmi R, Signore A, Papini E (2009) Low dose (2.0 GBq; 
54 mCi) radioiodine postsurgical remnant ablation in thyroid 
cancer: comparison between hormone withdrawal and use of 
rhTSH in low risk patients. Eur J Endocrinol 160:431–436
 16. Schlumberger M, Catargi B, Ph D, Borget I, Deandreis D, Zer-
doud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, 
Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax 
C, Toubert ME, Leboulleux S, Ricard M, Benhamou E (2012) 
Strategies of radioiodine ablation in patients with low-risk thy-
roid cancer. NEJM 366:1663–1673
 17. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol 
A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, 
John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-
Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan 
R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A 
(2012) Ablation with low-dose radioiodine and thyrotropin alfa 
in thyroid cancer. NEJM 366:1674–1685
 18. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, 
Grewal RK, Fleisher M, Robbins RJ (2008) Recombinant human 
TSH-assisted radioactive iodine remnant ablation achieves short-
term clinical recurrence rates similar to those of traditional thy-
roid hormone withdrawal. J Nucl Med 49:764–770
 19. Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, 
Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei 
R (2013) Patients with differentiated thyroid cancer who under-
went radioiodine thyroid remnant ablation with low-activity 131I 
after either recombinant human TSH or thyroid hormone therapy 
withdrawal showed the same outcome after a 10-year follow-up. 
J Clin Endocrinol Metab 98:2693–2700
 20. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier 
C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-
Devolx B, Loundou A, Auquier P, Henry JF, Mundler O (2009) 
Quality of life changes and clinical outcomes in thyroid cancer 
patients undergoing radioiodine remnant ablation (RRA) with 
346 J Endocrinol Invest (2016) 39:341–347
1 3
recombinant human TSH (rhTSH): a randomized controlled 
study. Clin Endocrinol 71:115–123
 21. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, 
Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard 
M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, 
Corone C, Reiners C (2006) Iodine biokinetics and dosimetry 
in radioiodine therapy of thyroid cancer: procedures and results 
of a prospective international controlled study of ablation after 
rhTSH or Hormone withdrawal. J Nucl Med 47:648–654
 22. Frigo A, Dardano A, Danese E, Davì MV, Moghetti P, Colato 
C, Francia G, Bernardi F, Traino C, Monzani F, Ferdeghini M 
(2009) Chromosome translocation frequency after radioiodine 
thyroid remnant ablation: a comparison between recombinant 
human thyrotropin stimulation and prolonged levothyroxine 
withdrawal. J Clin Endocrinol Metab 94:3472–3476
 23. Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlum-
berger M, De Pouvourville G (2008) Length and cost of hospital 
stay of radioiodine ablation in thyroid cancer patients: compari-
son between preparation with thyroid hormone withdrawal and 
thyrogen. Eur J Nucl Med Mol Imaging 35:1457–1463
 24. Tu J, Wang S, Huo Z, Lin Y, Li X, Wang S (2014) Recombinant 
human thyrotropin-aided versus thyroid hormone withdrawal-
aided radioiodine treatment for differentiated thyroid cancer after 
total thyroidectomy: a meta-analysis. Radiother Oncol 110:25–30
 25. Doi SA, Woodhouse NJ (2000) Ablation of the thyroid remnant 
and 131I dose in differentiated thyroid cancer. Clin Endocrinol 
(Oxf) 52:765–773
 26. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA (2007) 
131I activity for remnant ablation in patients with differentiated 
thyroid cancer: a systematic review. J Clin Endocrinol Metab 
92:28–38
 27. Rosario PW, Reis JS, Barroso AL, Rezende LL, Padrao EL, 
Fagundes TA (2004) Efficacy of low and high 131I doses for 
thyroid remnant ablation in patients with differentiated thyroid 
carcinoma based on post-operative cervical uptake. Nucl Med 
Commun 25:1077–1081
 28. Bal C, Padhy AK, Jana S, Pant GS, Basu AK (1996) Prospective 
randomized clinical trial to evaluate the optimal dose of 131 I 
for remnant ablation in patients with differentiated thyroid carci-
noma. Cancer 77:2574–2580
 29. Creutzig H (1987) High or low dose radioiodine ablation of thy-
roid remnants? Eur J Nucl Med 12:500–502
 30. Johansen K, Woodhouse NJ, Odugbesan O (1073) Comparison 
of MBq and 3700 MBq iodine-131 in postoperative ablation of 
residual thyroid tissue in patients with differentiated thyroid can-
cer. J Nucl Med 32:252–254
 31. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, 
Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo 
A, Cipri C, Pacini F (2007) A comparison of 1850 (50 mCi) 
and 3700 MBq (100 mCi) 131-iodine administered doses for 
recombinant thyrotropin-stimulated postoperative thyroid rem-
nant ablation in differentiated thyroid cancer. J Clin Endocrinol 
Metab 92:3542–3546
 32. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu 
H (2008) Low vs. high radioiodine activity to ablate the thyroid 
after thyroidectomy for cancer: a randomized study. PLoS One 
3:e1885
 33. Castagna MG, Cevenini G, Theodoropoulou A, Maino F, 
Memmo S, Cipri C, Belardini V, Brianzoni E, Pacini F (2013) 
Post-surgical thyroid ablation with low or high radioiodine activ-
ities results in similar outcomes in intermediate risk differenti-
ated thyroid cancer patients. Eur J Endocrinol 169:23–29
 34. Franzius C, Dietlein M, Biermann M, Frühwald M, Linden T, 
Bucsky P, Reiners C, Schober O (2007) Procedure guideline for 
radioiodine therapy and 131iodine whole-body scintigraphy in 
paediatric patients with differentiated thyroid cancer. Nuklear-
medizin 46:224–231
 35. Jarzab B, Handkiewicz-Junak D, Wloch J (2005) Juvenile dif-
ferentiated thyroid carcinoma and the role of radioiodine in its 
treatment: a qualitative review. Endocr Relat Cancer 12:773–803
 36. Lassmann M, Hanscheid H, Chiesa C, Hindorf C, Flux G, Luster 
M (2008) EANM dosimetry committee series on standard opera-
tional procedures for pre-therapeutic dosimetry. I: blood and 
bone marrow dosimetry in differentiated thyroid cancer therapy. 
Eur J Nucl Med Mol Imaging 35:1405–1412
 37. Oliynyk V, Epshtein O, Sovenko T, Tronko M, Elisei R, Pacini F, 
Pinchera A (2001) Post-surgical ablation of thyroid residues with 
radioiodine in Ukrainian children and adolescents affected by 
post-chernobyl differentiated thyroid cancer. J Endocrinol Invest 
24:445–447
 38. Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati 
S, Mete M, Burman K, Wartofsky L (2010) (124)I positron emis-
sion tomography versus (131)I planar imaging in the identifica-
tion of residual thyroid tissue and/or metastasis in patients who 
have well-differentiated thyroid cancer. Thyroid 20:879–883
 39. Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F 
(1997) Predicting the efficacy of first iodine-131 treatment in dif-
ferentiated thyroid carcinoma. J Nucl Med 38:1362–1368
 40. Leger AF, Pellan M, Dagousset F, Chevalier A, Keller I, Clerc J 
(2005) A case of stunning of lung and bone metastases of papil-
lary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I 
and review of the literature: implications for sequential treat-
ments. Br J Radiol 78:428–432
 41. Park HM, Park YH, Zhou XH (1997) Detection of thyroid rem-
nant/metastasis without stunning: an ongoing dilemma. Thyroid 
7:277–280
 42. Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed 
NS (2002) Self-stunning in thyroid ablation: evidence from com-
parative studies of diagnostic 131I and 123I. Eur J Nucl Med 
Mol Imaging 29:783–788
 43. McMenemin RM, Hilditch TE, Dempsey MF, Reed NS (2001) 
Thyroid stunning after (131)I diagnostic whole body scanning. J 
Nucl Med 42:986–987
 44. Silberstein EB (2007) Comparison of outcomes after (123)I ver-
sus (131)I pre ablation imaging befre radioiodine ablation in dif-
ferentiated thyroid carcinoma. J Nucl Med 48:1043–1046
 45. Verburg FA, Verkooijen RB, Stokkel MP, Van Isselt JW (2009) 
The success of I131 ablation in thyroid cancer is significantly 
reduced after a diagnostic activity of 40 MBq I131. Nuklear-
medizin 48:138–142
 46. Robenshtok E, Grewal RK, Fish S, Sabra M, Thyroid Tuttle RM 
(2013) A low postoperative nonstimulated serum thyroglobulin 
level does not exclude the presence of radioactive iodine avid 
metastatic foci in intermediate-risk differentiated thyroid cancer 
patients. Thyroid 23:436–442
 47. Rosario PW, Xavier AC, Thyroid Calsolari MR (2011) Value of 
post- operative thyroglobulin and ultrasonography for the Indica-
tion of ablation and 131I activity in patients with thyroid cancer 
and low risk of recurrence. Thyroid 21:49–53
 48. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong 
SJ, Shong YK (2005) Serum thyroglobulin levels at the time 
of 131I remnant ablation just after thyroidectomy are useful 
for early prediction of clinical recurrence in low-risk patients 
with differentiated thyroid carcinoma. J Clin Endocrinol Metab 
90:1440–1445
 49. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, 
Pasqui L, Sestini F, Theodoropoulou A, Pacini F (2011) The use 
of ultrasensitive thyroglobulin assays reduces but does not abol-
ish the need for TSH stimulation in patients with differentiated 
thyroid carcinoma. J Endocrinol Invest 34:e219–e223
347J Endocrinol Invest (2016) 39:341–347 
1 3
 50. Maxon HR, Thomas SR, Boehringer A, Drilling J, Sperling MI, 
Sparks JC, Chen IW (1983) Low iodine diet in I-131 ablation of 
thyroid remnants. Clin Nucl Med 8:123–126
 51. Goslings BM (1975) Proceedings: effect of a low iodine diet on 
131-I therapy in follicular thyroid carcinomata. J Endocrinol 
64:30P
 52. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, 
Arias AM, Diamant M, Romijn JA, Smit JW (2003) Effects of 
low-iodide diet on postsurgical radioiodide ablation therapy in 
patients with differentiated thyroid carcinoma. Clin Endocrinol 
(Oxf) 58:428–435
 53. Lazarus JH (2014) Iodine status in europe in 2014. Eur Thyroid 
J. 3:3–6
 54. Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-
Fatourechi GZ, Thorson LM, Gorman CA (2000) Are post-
therapy radioiodine scans informative and do they influence 
subsequent therapy of patients with differentiated thyroid can-
cer? Thyroid 10:573–577
 55. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW 
(1994) Clinical utility of posttreatment radioiodine scans in the 
management of patients with thyroid carcinoma. J Clin Endo-
crinol Metab 78:629–634
 56. Souza Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagun-
des TA, Penna GC, Purisch S (2004) Post I-131 therapy scanning 
in patients with thyroid carcinoma metastases: an unnecessary 
cost or a relevant contribution? Clin Nucl Med 29:795–798
 57. Maruoka Y, Abe K, Baba S, Isoda T, Sawamoto H, Tanabe 
Y, Sasaki M, Honda H (2012) Incremental diagnostic value of 
SPECT/CT with 131I scintigraphy after radioiodine therapy in 
patients with well-differentiated thyroid carcinoma. Radiology 
265(3):902–909
